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Abstract: Alternative splicing plays an important role in numerous cellular processes and aberrant
splice decisions are associated with cancer. Although some studies point to a regulation of alternative
splicing and its effector mechanisms in a time-dependent manner, the extent and consequences of such
a regulation remains poorly understood. In the present work, we investigated the time-dependent
production of isoforms in two Hodgkin lymphoma cell lines of different progression stages (HD-MY-Z,
stage IIIb and L-1236, stage IV) compared to a B lymphoblastoid cell line (LCL-HO) with a focus
on tumour necrosis factor (TNF) pathway-related elements. For this, we used newly generated
time-course RNA-sequencing data from the mentioned cell lines and applied a computational pipeline
to identify genes with isoform-switching behaviour in time. We analysed the temporal profiles of
the identified events and evaluated in detail the potential functional implications of alterations in
isoform expression for the selected top-switching genes. Our data indicate that elements within the
TNF pathway undergo a time-dependent variation in isoform production with a putative impact on
cell migration, proliferation and apoptosis. These include the genes TRAF1, TNFRSF12A and NFKB2.
Our results point to a role of temporal alternative splicing in isoform production, which may alter the
outcome of the TNF pathway and impact on tumorigenesis.
Keywords: circadian clock; cancer; systems biology; high-throughput data analysis; alternative
splicing; analysis of oscillating genes; pathway enrichment; RNA-sequencing; TNF-pathway
1. Introduction
Alternative splicing (AS) belongs to one of the key biological processes, which regulates gene
expression diversity and function in eukaryotes. In this process, different coding regions of the
pre-mRNA are included in the mature mRNA in a combinatorial way. This leads to exon/intron
inclusion or exclusion events in the final transcript form of a gene. As a result, AS is able to generate a
myriad of functional proteins from the same gene. This affects cellular functions and pathways, and
provides the organism an evolutionary advantage to adapt to its changing environment. Remarkably,
it was estimated that around 95% of human genes are alternatively spliced [1,2]. Moreover, AS can
influence different aspects of protein functionality including protein localization, protein–protein
binding and catalytic properties of proteins [3]. Also cellular phenotypes (e.g., apoptosis and
proliferation), as well as regulation of gene expression and histone modification can be fine-tuned
by AS events [3]. Therefore, failures in splicing decisions (e.g., due to genetic mutations leading to
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sequence alterations within the transcript, which may alter the sequences of splice sites) or within the
splicing machinery (e.g., in small nuclear ribonucleic particles snRNPs) may lead to the generation of
aberrant transcripts and contribute to human disease [4,5].
In cancer, changes of AS are well studied, and a deregulated AS is reported as one of the hallmarks
of cancer [6,7]. Several protein isoforms generated by alternative splicing are crucial for cancer
progression and are the subject of experimental therapeutic interventions [8]. One example is the RON
(tyrosine kinase receptor) gene, which is involved in cell motility and invasion. A constitutively active
isoform of this gene (delta-Ron) is generated via the skipping of an alternative exon regulated by the
splicing factors SF2/ASF. It was shown that overexpression of SF2/ASF isoform translates into the
constitutively active form of the RON kinase that determines the epithelial to mesenchymal transition
facilitating invasion, intravasation and extravasation, known steps of metastasis [9]. Another example
is the splicing factor SRSF6, which via a fine-tuning of its expression, is able to alter the splicing of
several oncogenes, including the insulin receptor (INSR), the kinase Mnk2 (MKNK2) and the discs
large MAGUK scaffold protein 1 (DLG1) leading to the production of oncogenic isoforms or to the
reduction of the tumour-suppressing isoforms [10].
Several studies have illustrated a cancer-specific pattern of AS in various cancer types (e.g., in
neuroblastoma, Hodgkin lymphoma (HL), prostate, colon and lung cancers) [11–15]. In particular,
the analysis of AS using microarray data in HL revealed stage–specific patterns of AS between HL
cell lines of different tumour stages [13]. Interestingly, HL tumours of the same stage (HDML-2 and
L-540, stage IV) showed greater similarity in their splicing pattern (70% similarity) when compared
to a HL cell line from a different stage (HD-MY-Z, stage IIIb, 55% similarity). These patterns also
enabled the establishment of a differential genetic signature between HL tumours and a non-tumour B
lymphoblastoid cell line (LCL-HO). Additionally, several splicing factors (e.g., hnRNP E1, U2AF65
and NOVA-1/2) were reported to be differentially expressed in the HL cell lines as compared to the B
lymphoblastoid cell line (LCL-HO). These findings point to the relevance of splicing in tumorigenesis
for this cellular model of HL [13].
Increasing evidence points to the regulation of several post-transcriptional processes in a time-
dependent manner. Genes and proteins hallmarked by circadian (ca. 24 h period) and ultradian
(between 8–12 h period) expression were shown to be conserved across several species and regulate
several pathways [16]. These include AS, polyadenylation, mRNA stability and mRNA transport [17].
Additionally, several RNA-binding proteins involved in AS regulate the expression, localization and
translation of core-clock components (e.g., Per1 and CLOCK) [18–20]. Altogether, these findings
indicate a role of splicing in the regulation or fine-tuning of the circadian machinery and vice versa
with a potential impact in tumorigenesis.
One of the pathways for which published data points to a role of AS in the regulation of elements
of the signalling cascade is the TNF (tumour necrosis factor) pathway [21]. As demonstrated by
many studies, TNF plays a central role in diverse cellular events such as inflammation, immunity,
cell proliferation, differentiation and apoptosis [22–24]. Hence, TNF can activate several downstream
elements to induce differential cellular responses through the activation of TNF receptor elements
(TNFRs), members of the TNF superfamily receptors. This activation, in turn, can induce the initiation
of diverse signalling cascades leading to apoptosis (via the TNFR1-associated death domain protein
TRADD) or inflammation and proliferation (via the activation of TNF receptor-associated factors
TRAFs, NF-kB activation as well as the c-Jun N-terminal kinase (JNK)-dependent kinase cascade) [25].
Consequently, TNF is involved in many aspects of tumorigenesis by inducing tumour suppression
(activating apoptosis as described above), as well as tumour initiation and progression. This is achieved
mostly via the activation of NF-kB- and activator protein 1 (AP-1)-dependent pathways [24,25], or
enhancing angiogenesis through various angiogenic factors such as vascular endothelial growth
factor (VEGF) and the JNK-dependent pathway [26]. Given the AS properties described above, it is
conceivable that AS-generated isoforms within the elements of the TNF signalling pathway may play
a major role in the balance between TNF-induced survival, inflammation and apoptosis.
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Despite the increasing relevance of the time-dependent regulation of cellular processes in cancer
progression, the impact of circadian regulation in splicing remains poorly understood. Thus, it is
of great biological and clinical relevance to identify timely regulated AS events among elements
of the TNF pathway in cancer cellular models. Yet, additional studies at the transcriptome level
using circadian data sets are still rare and are essential for the investigation of time-dependent AS
regulation [27,28].
In this work, we characterized the extent of a time-dependent isoform generation in elements
within the TNF pathway. We generated 33 time-course data sets (sampling every three hours between
ZT12 h and ZT42 h) to investigate the time-dependent production of isoforms in two HL cell lines at
different stages (HD-MY-Z, stage IIIb and L-1236, stage IV) compared to a B lymphoblastoid cell line
(LCL-HO) with a focus on TNF pathway-related elements. ZT (zeitgeber time) is defined as the time (in
hours) after cell synchronization with medium change. Using a computational approach, we identified
several genes involved in the TNF pathway to undergo a time-dependent change in isoform expression
with potential implications on the output of the pathway. These include TNF receptor-associated factor
1 (TRAF1), TNF receptor superfamily 12A (TNFRSF12A) and the nuclear factor kappa B subunit 2
(NFKB2) with relevant functions in cell proliferation, migration and apoptosis. Our results further
emphasize the potential impact of AS in cellular physiology, in a cancer context, and highlight the
effect of temporal isoform switching events as mediators of these processes.
2. Results
2.1. Computational Analysis of RNA-Seq Time Series Data Reveals a High Number of Time-Dependent
Splicing Switches between Isoforms in the LCL-HO, HD-MY-Z and L-1236 Cell Lines
Previous research pointed at the relevance of splicing in cancer, and identified cell-specific
AS changes in HL cell lines [4,13,29]. In order to investigate the time-distribution of the isoforms
detected in haematological cell lines we used a B lymphoblastoid cell line LCL-HO, the Hodgkin
lymphoma cell lines HD-MY-Z (stage IIIb) and L-1236 (stage IV) and generated a total of 33 time-course
data sets (sampling every three hours between ZT12 h and ZT42 h), which were subsequently
sequenced. We used the 33 data sets as the input for our computational analysis pipeline (Figure 1A).
We quantified paired-end RNA-Seq data with the Salmon software by using the European Molecular
Biology Laboratory (EMBL) reference transcriptome Homo_sapiens.GRCh38.cdna. We used the
quantified transcripts in TPM (transcripts per million) to analyse the isoform expression profiles over
time, identified switches in the expression of isoforms from the same set of genes with the TSIS R
package [30], and further investigated the switches regarding their potential functionality. Isoform
switching is defined as the reversal of relative abundance of different isoforms of the same gene over
time. Interestingly, the number of switches and their distribution over time varies greatly between the
cell lines (Figure 1B). We filtered the switching events with a p-value cut-off of 0.001, and a difference
cut-off of 1 as suggested in the TSIS package (see Materials and Methods for details) [30]. The difference
cut-off is defined as the sum of the average abundance differences in TPM of the two isoforms in the
intervals before and after the switch. This indicates the magnitude of the switch. Higher values mean
larger changes in expression before and after the switch. Once we identified potential switches, we
performed a downstream analysis with the IsoformSwitchAnalyzeR R package [31] for coding potential
and signatures of functional domains. Furthermore, we performed a Reactome pathway enrichment
analysis for the groups of genes containing isoform switches. For the LCL-HO, we detected 881
switches in pairwise isoform expression in time (Table S1) with one switch time peak (LCL-HO_STP1)
containing 273 switching events in pairwise isoform expression in a 3 h bin between 27 h and 30 h.
A STP is defined as a peak in the distribution of isoform switching events per 3 h bin as computed by
the TSIS algorithm. For the HD-MY-Z we detected 1865 switches between isoforms (Table S2) and one
STP (HD-MY-Z_STP1) with 783 switching events in pairwise isoform expression in a 3 h bin between
33 h and 36 h. For the L-1236 cell line we detected 755 switches between isoforms (Table S3) and three
STPs at 18 h to 21 h (L-1236_STP1, 166 switching events), 24 h to 27 h (L-1236_STP2, 167 switching
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events) and 36 h to 39 h (L-1236_STP3, 148 switching events), as depicted in Figure 1B. Interestingly,
this might indicate a specific pattern of STP distribution that could correlate to the clinical stage of the
cancer (HD-MY-Z vs L-1236), so that the higher stage cell line contains more STPs.
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Figure 1. Analysis of isoform expression switching over time shows an enrichment of switching events
in a time-specific manner (A) Schematic representation of the pipeline for the detection and analysis
of isoform switching events. (B) Distribution of isoform-switching eve t for all genes over time.
The LCL-HO cell line shows only one switch time peak ( P) between 27 h and 30 h ( STP1, 273
switching events), the HD-MY-Z cell line shows a STP between 33 h and 36 h (STP1, 783 switching
events) and the L-1236 cell line shows three STPs between 18 h to 21 h (STP1, 166 switching events),
24 h to 27 h (STP2, 167 switching events) and 36 h to 39 h (STP3, 148 switching events).
2.2. The Switch Time Peaks (STPs) Are Characterized by Trends in Function l Changes such as the Transcript
Coding Potential, Domain Contents and Sensitivity to Nonsense-Mediated Decay
We further investigated the switches between isoforms in time, focusing in the region around
the STPs, and tested for potential functional properties of the resulting transcripts at the sequence
level (Figure 2, Figures S1–S3). Such properties include the coding potential of the transcripts (CP),
the potential protein domains identified based on the s qu nce of the transcript (domains identified),
intron retention properties (IR), the susceptibility of the transcript to nonsense-mediated decay (NMD),
and the similarity of the ORF sequence between the time-points (ORF seq similarity). We found large
differences in the functional outcome of the switching events between the cell lines LCL-HO and
HD-MY-Z (Figure 2A,B, respectively). For the LCL-HO cell line the STP between 27 h a d 30 h shows
an increase of coding transcripts combined with longer ORFs and domain gains (Figure 2A), however
this difference is not statistically significant (Figure S1). For the STP of the HD-MY-Z cell line between
33 h and 36 h we detected a significant increase (Figure S1) of the number of non-coding transcripts
and, therefo e, domain loss in the sequence with corresponding shorter ORF (Figure 2B). The three
STPs of the L-1236 cell line lead to interesting observations (Figure 2C–E). The STP1 between 18 h and
21 h shows a statistically significant (with confidence interval of 95%) increase of coding transcripts
with domain gains and longer ORFs (Figure 2C and Figure S1). The second and third STPs (STP2,
between 24 h to 27 h and STP3, 36 h to 39 h, respectively) show several switches towards isoforms with
shorter ORFs and domain loss (Figure 2D,E, respectively). Based on our findings, the STPs between
24 h to 27 h and 36 h to 39 h in the L-1236 cell line are similar to the STP of HD-MY-Z between 33 h
and 36 h, which could indicate a potential relevance of the temporal distribution of the STPs to its
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functional outcome in each cell line. The changes in transcript length and potential functionality
between the STPs relate to changes in the alternative splicing events over time (Figures S2 and S3).
In all cases, alternative transcription stop- and start-sites are the mechanisms by which most of the
changes in isoform balance are generated.
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Figure 2. Computational analysis of the isoforms involved in the STPs shows that the loss of coding
functionality and potential domain loss are the main consequences of changes in isoform expression.
We performed computational analysis only on the highly expressed genes and iso orms with changing
expression in each STP. The analysis included coding potential (CP), identification of potential domains
(domains ident.), possible intron retention (IR), nonsense-mediated decay (NMD) and open reading
frame (ORF) length and availability (ORF seq similarity). (A) The STP between 27 h and 30 h for the
LCL-HO cell line shows an increase in coding transcripts for the upregulated isoforms leading to gains
in potential domains and increase of ORF length. (B) The STP between 33 h and 36 h for HD-MY-Z
shows an increase of non-coding transcripts and a related loss of potential domains. The shorter ORF
or its complete loss means that sequence elements coding for potential domains are lost. (C) The STP at
18 h to 21 h for the L-1236 cell line shows an increase in coding transcripts for the upregulated isoforms
leading to gains in potential domains, and increase of ORF length. (D,E) The STPs at 24 h to 27 h and
36 h to 39 h (respectively) for the L-1236 cell line show an increase of non-coding transcripts and a
related loss of potential domains with an increase in both complete ORF loss and shorter ORFs.
Int. J. Mol. Sci. 2019, 20, 1182 6 of 20
2.3. The Genes for which Switches in Isoform Expression Were Detected in Each Cell Line Show a Specific
Enrichment of Functionality Focused on the SLIT/ROBO, Sterol Regulatory Element-Binding Proteins
(SREBP) and Circadian Clock Pathways
The switches detected for all cell lines, at the gene level, vary between 547 genes with switches
between isoform-pairs for the LCL-HO cell line (Figure 3A, Table S4), 958 genes with switches for the
HD-MY-Z cell line (Table S5), and 460 genes with switches for the L-1236 cell line (Table S6). Some
genes have multiple pairs of isoforms switching in time hence the number of switching events is
greater than the number of genes. A core set of 89 genes with isoform switches is common between
the three cell lines (Table S7). This core set shows enrichment of Reactome pathway terms related
to translation and splicing (adjusted (BH) p-value = 8.360 × 10−7) as well as NMD (adjusted (BH)
p-value = 1.870 × 10−3) (Figure 3B, Table S8). Additionally, we performed an enrichment analysis
for disease ontology pathways using the 89 gene sets (Figure 3C, Table S9). The genes with switches
identified by our data (e.g., VEGFA) are involved in a variety of cancers including skin, pancreatic and
colon cancer, as well as lung disease according to our enrichment analysis, which is in agreement with
previous studies for the mentioned gene [32]. However, when analysing the gene sets of the individual
cell lines for which switching in isoform production was detected we observed a more diverse scenario
(Figure 3D, Tables S10–S12). For the B lymphoblastoid LCL-HO cell line (547 genes with identified
switches), there is an enrichment of ROBO-related pathways (Table S10, adjusted (BH) p-value =
7.099 × 10−8). The SLIT/ROBO pathway has important roles in tumorigenesis, cancer progression
and metastasis and thus acts as a regulator for multiple oncogenic signalling pathways including
the CD20, mTOR (mammalian target of rapamycin), VEGF and EGFR (epidermal growth factor
receptors) pathways [33]. The ROBO functionality can also be found in the enriched pathways for the
HD-MY-Z cell line (Table S14) regulation of expression of SLITs and ROBOs, (adjusted (BH) p-value =
6.918 × 10−3), interestingly only in the genes with switches that are unique to this cell line (620 unique
genes with identified switches, Figure S4), hence different genes of the same pathway are affected. The
L-1236 cell line (460 genes with identified switches), however, shows an interesting enrichment of the
FGFR2 (Table S12, fibroblast growth factor receptor 2, adjusted (BH) p-value = 3.640 × 10−4) signalling
pathway, which is associated with disrupted organogenesis leading to cancer [34]. Additionally, we
performed an enrichment analysis on the set of unique genes for each cell lines for Reactome pathways
and disease ontology (Figure S4, Tables S13–S15). In addition to RNA splicing and translation-related
pathways, we found metabolic (metabolism of steroids, p-value = 4.542 × 10−2), the SREBP (sterol
regulatory element-binding proteins) pathway (regulation of cholesterol biosynthesis by SREBP, p-value
= 5.090 × 10−3 and activation of gene expression by SREBF, p-value = 4.542 × 10−2) and the circadian
clock pathway (p-value = 4.542 × 10−2) to be enriched in the L-1236 cell line (Table S15). SREBP
belongs to transcription factors that regulate the expression of genes required for the synthesis of
fatty acids and cholesterol and thus is relevant for cellular metabolism. For the LCL-HO cell line, the
disease ontology enrichment for the unique switching genes shows cancer-related terms (Figure S4,
Table S16). For the HD-MY-Z cell line, this result is more striking with 7 out of the top 10 disease
ontology-enriched terms being cancer-related (Table S17).
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the cell lines analysed (A) We detected an intersection of 89 genes for the three cell lines, for the
genes for hich switching in isoform expression was detected in our analysis. (B) The top enriched
pathways for the 89 genes are mRNA splicing and translation, as well as the processing of capped
intron-containing pre-mRNA. (C) All but one of the top 10 enriched disease ontology terms associated
with the 89 genes are different forms of cancer. (D) We analysed all genes for which switches in isoform
expression over time were detected for the three cell lines. A set of common pathways including mRNA
splicing, translation and ribosomal activity was identified for all cell lines, the L-1236 cell line shows an
additional enrichment for the FGFR2 pathway.
2.4. Several Genes Display Switching in Isofor Production ver Ti e
We computed the difference in expression between the switching isoforms with the TSIS
package [30] and generated lists with all switching events for the three cell lines (Tables S1–S3). We
plotted several gene isoforms out of the top 20 events (Figure 4) to illustrate the temporal changes in
the expression of the isoforms. For the LCL-HO (Figure 4A) cell line HNRNPH1 (heterogeneous nuclear
ribonucleoprotein H1) shows an absolute difference of expression of 701.44 TPM between the isoforms
ENST00000262584.7 and ENST00000526668.5. JCHAIN (joining chain of multimeric IgA and IgM)
shows an absolute difference in expression of 107.69 TPM between the isoforms ENST00000510437.5
and ENST00000543780.5 and NME2 (NME/NM23 nucleoside diphosphate kinase 2) shows an
absolute difference in expression of 408.09 TPM between the isoforms ENST00000513177.5 and
ENST00000512737.5. The HNRNPH1 gene is involved in splicing. It is overexpressed in many cancer
types (e.g., rhabdomyosarcoma, esophageal squamous cell carcinoma and breast cancer) and is required
for cancer growth and development [35–37]. Notably, the expression of the two isoforms of HNRNPH1
is different over time f r the three investigated cell lines (Figure S5). There is no switch between
the expression of the same two is forms o HNRNPH1 in HD-MY-Z an multiple switches in our
data for L-1236. JCHAIN is involved in innate and a aptive immune response, and is differentially
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expressed in different cancer types (e.g., colon and prostate cancer) [38]. NME2 is involved in myeloid
differentiation, apoptosis and cell development. It acts as a transcriptional activator of the MYC gene
and its isoforms, which are either differentially or ubiquitously expressed [39].
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 20 
 
cancer) [38]. NME2 is involved in myeloid differentiation, apoptosis and cell development. It acts as 
a transcriptional activator of the MYC gene and its isoforms, which are either differentially or 
ubiquitously expressed [39].  
For the HD-MY-Z (Figure 4B) cell line the CD44 gene shows an absolute difference in expression 
between the isoforms ENST00000263398.10 and ENST00000352818.8 of 164.95 TPM. The TNFRSF12A 
gene shows an absolute difference in expression of 211.08 TPM for the isoforms ENST00000326577.8 
and ENST00000341627.5 and the HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1) gene 
(involved in splicing and mRNA transport) shows an absolute difference in expression of 171 TPM 
for the isoforms ENST00000340913.10 and ENST00000547566.5. CD44 encodes for a cell-surface 
glycoprotein and can act both as a growth- and invasiveness-promoting molecule, and as a tumour-
suppressing cofactor via its different splice variants [40]. TNFRSF12A belongs to the TNF superfamily 
and is involved in angiogenesis, cell migration and apoptosis.  
For the L-1236 cell line (Figure 4C), the NFKB2 gene shows an absolute difference of 84.39 TPM 
between the isoforms ENST00000189444.10 and ENST00000467116.5, the PPP4C (protein 
phosphatase 4 catalytic subunit) gene shows an absolute difference of 147.32 TPM between the 
isoforms ENST00000279387.11 and ENST00000561610.1. The HSPD1 (heat shock protein family D 
(Hsp60) member 1) gene shows an absolute difference in expression of 348.472 TPM between the 
isof rms ENST00000388968.7 and ENST00000345042.6. PPP4C mediates the repair process  
damaged DNA upon double strand break and HSPD1 is involved in B and T cell activation, among 
other processes. NFKB2 is a member of NF-KB family of proteins and of the TNF signalling pathway. 
It is involved in transcription, differentiation, apoptosis and inflammatory response. Altogether, 
these results indicate that a time-dependent change in isoform expression is present in genes with an 
impact on vital cellular processes.  
 
Figure 4. Several of the genes with largest expression difference between the switching isoforms are 
related to the tumour necrosis factor (TNF)-signalling pathway. (A) Out of the top 20 genes with 
largest expression difference between the isoforms for the LCL-HO cell line are the JCHAIN, NME2 
Figure 4. Several of the ith largest expression differenc between the switching isofo ms
are related to the tumour necrosis factor (TNF)-sig alling p thway. (A) Out of the top 20 genes
with largest expression difference b twe n the isoforms for the LCL-HO cell line are the JCHAIN,
NME2 and HNRNPH1 genes, which depict remarkable difference in expression patterns over time.
(B) Central genes involved in cancer metastasis such as CD44 undergo switching in isoform expression
in HD-MY-Z. TNFRSF12A is related to the TNF-signalling pathway. (C) The changes in the expression
of NFKB2 in L-1236 are associated to the TNF signalling pathway, and suggest possible rhythmicity
of isoform expression switching. Also the expression changes between isoforms for PPP4C show a
circadian pattern.
For the HD-MY-Z (Figure 4B) cell line the CD44 gene shows an absolute difference in expression
between the isoforms ENST00000263398.10 and ENST00000352818.8 of 164.95 TPM. The TNFRSF12A
gene shows an absolute difference in expression of 211.08 TPM for the isoforms ENST00000326577.8 and
ENST00000341627.5 and the HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1) gene (involved
in splicing and mRNA transport) shows an absolute difference in expression of 171 TPM for the
isoforms ENST00000340913.10 and ENST00000547566.5. CD44 encodes for a cell-surface glycoprotein
and can act both as a growth- and invasiveness-promoting molecule, and as a tumour-suppressing
cofactor via its different splice variants [40]. TNFRSF12A belongs to the TNF superfamily and is
involved in angiogenesis, cell migration and apoptosis.
For the L-1236 cell line (Figure 4C), the NFKB2 gene shows an absolute difference of 84.39
TPM between the isoforms ENST00000189444.10 and ENST00000467116.5, the PPP4C (protein
phosphatase 4 catalytic subunit) gene shows an absolute difference of 147.32 TPM between the
isoforms ENST00000279387.11 and ENST00000561610.1. The HSPD1 (heat shock protein family D
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(Hsp60) member 1) gene shows an absolute difference in expression of 348.472 TPM between the
isoforms ENST00000388968.7 and ENST00000345042.6. PPP4C mediates the repair process of damaged
DNA upon double strand break and HSPD1 is involved in B and T cell activation, among other
processes. NFKB2 is a member of NF-KB family of proteins and of the TNF signalling pathway. It is
involved in transcription, differentiation, apoptosis and inflammatory response. Altogether, these
results indicate that a time-dependent change in isoform expression is present in genes with an impact
on vital cellular processes.
2.5. Multiple Genes Involved in the Tumour Necrosis Factor (TNF) Pathway or Related to TNF Signalling
Switch between Isoforms in a Time-Dependent Manner
Interestingly, several of the top switching genes such as TNFRSF12A and NFKB2 are related to the
TNF pathway. Therefore, we investigated the TNF pathway in detail and detected multiple switches
in isoform expression over time in several genes. These included TRAF1 and RACK1 (receptor for
activated C kinase 1) in the LCL-HO cell line (Figure 5A), RACK1 and SHARPIN (SHANK associated
RH domain interactor) in the HD-MY-Z cell line (Figure 5B), as well as in UBB (ubiquitin B) and
RPS27A (ribosomal protein S27a) for the L-1236 cell line (Figure 5C).
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time. (A) For the LCL-HO cell line the TRAF1 and RACK1 genes show a differential expression
of the corresponding isoforms. (B) For the HD-MY-Z cell line, the RACK1 gene shows switching
behaviour between the isoforms. Multiple isoforms of the gene show a switch phenotype over time.
The SHARPIN gene shows switching of isoform expression at 36h-39h, corresponding to STP1 for the
cell line HD-MY-Z. (C) For the L-1236 only the genes UBB and RPS27A are affected by switching in
time between isoform expression within the TNF pathway.
The presence of switches in isoform expression over time and their concentration at specific time
points has potential functional implications on the function of the generated protein and the subsequent
alterations in the phenotype of the cell. To investigate this aspect in more detail, we performed
an analysis at the sequence level with the R package IsoformSwitchAnalyzeR that allows for the
integration of data from tools such as CPAT (coding-potential assessment tool) [41] for coding potential
analysis and PFAM (protein family) [42] for potential protein domain identification. We focused
on the genes TNFRSF12A, CD44 and NFKB2 in more detail given their role in the multiple cellular
pathways and cancer and the high scoring of the corresponding switching events. We investigated all
isoforms with high expression for the corresponding genes. We observed large changes in expression
for the TNFRSF12A gene in the HD-MY-Z cell line (Figure 6A). For TNFRSF12A the switch between
the isoforms ENST00000326577.8 and ENST00000341627.5 leads to a change between a coding and
a non-coding isoform, meaning that the corresponding stn_TNFRSF12A domain will be affected
and the non-coding isoform contributes more to the summed up expression of the gene. Similarly,
while multiple isoforms of CD44 are affected by changes over time, this effect is most dramatic
regarding the coding isoform ENST00000528086.5, with a signal that nearly disappears within 9 h
(Figure 6B).The overall cumulative expression of the gene shows only a minor change of 4.05% from
773.27 TPM to 804.55 TPM, underscoring the importance of isoform-level investigation. Similarly,
the genes NME2 and JCHAIN in LCL-HO show larger changes between the expression of isoforms
than the total expression of the gene (Figure S6). For the L-1236 cell line, we identified a switch with
potential major implication between the isoforms ENST00000189444.10 and ENST00000467116.5 of
NFKB2. ENST00000467116.5 does not contain the important death domain, central in the regulation of
apoptosis and inflammation. Additionally the multiple Ank (Ankyrin) domains are absent. These are
critical for folding and stability and are involved in protein-protein interactions. As mentioned above,
the cumulative expression of the gene shows little variations (6.93% from 411.96 TPM to 382.52 TPM)
whereas the expression of the isoforms shows strong differences within six hours. These findings point
to the potential implication of temporal switching events in isoform expression and its impact in the
subsequent protein functions.
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isoforms (Figure 4A), we further investigated the potential functionality of the isoforms. The two
isoforms of TNFRSF12A have different predicted functionality. ENST00000326577.8 has predicted
coding functionality and a stn_TNFRSF12A domain, whereas the ENST00000341627.5 is predicted to
be non-coding. (B) The CD44 gene with its multiple isoforms illustrates the importance of alternative
splicing: the total gene expression is almost unchanged between the time points 30 h and 39 h, however
the individual isoforms show a larger deviation in expression. Most notably, the ENST00000528086.5
isoform, predicted to be coding, is almost absent at 39 h. (C) In the L-1236 cell line we detected changes
in isoform balance in the NFKB2 gene (Figure 4C). The total expression of the gene shows only a
minor change between the time points, however the isoform ENST00000467116.5 lacking the important
death-domain is upregulated at 30 h as compared to 24 h (STP2).
The abundance of time-dependent changes of isoform expression in the TNF pathway (Figure 7)
points to a possible change of the output of the pathway within a day. The TNF pathway is activated
through the binding of TNF to its receptors (TNFR1 and TNFR2) leading to the activation of several
signalling cascades. While the activation of the TNFR1 mainly results in the activation of cellular
components leading to cell apoptosis, TNFR2 induction is required for cell survival and inflammation
responses [25]. One of the main components of the latter pathway is the TRAF complex (TRAF1,
TRAF2 and inhibitor of apoptosis proteins cIAPs), which regulates several downstream signalling
pathways, including survival and inflammation through the NF-kB pathway and cell apoptosis via
interactions with the LUBAC (linear ubiquitin assembly complex) [24,25].
Results from our computational analysis revealed that in all of the investigated cell lines, we
found a TNF or TNF-related element with temporal changes in isoform production. We identified
TRAF1 in the LCL-HO cell line, TNFRSF12A and RACK1 in the HD-MY-Z cell line and NFKB2 in the
L-1236 cell line, which show significant isoform switching behaviour and can regulate the resulting
output of the TNF signalling pathway in this cellular model system.
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3. Discussion
In the present study, we characterized the existence of time-dependent AS events in HL cell lines
(HD-MY-Z, stage IIIb and L-1236, stage IV) and a non-tumour B lymphoblastoid cell line (LCL-HO)
using a computational approach. Stage-specific patterns of AS and splicing factor expression for
HL cells from different tumour stages has previously been reported [13]. The authors made use
of these patterns to classify the stage of each tumour and to distinguish between a non-tumour B
lymphoblastoid cell line and cancer cells [13]. To date, no corr lation between the splicing events and
the circadian clock have been investigated for this cellular system.
3.1. Differential Number of Splicing Switches in Cancer Cell Lines Correlate with Tumour Progression Stage
Published data points to the regulation of AS, and various post-translational processes by the
circadian clock pointing to a time-dependency of such molecular mechanisms with implications in
cellular function [17,27]. To investigate this in detail, we performed a time-course genome-wide
screening of the two HL cell lines and the non-tumour B lymphoblastoid cell line and carried out a
detailed computational analysis of the generated 33 sets of RNA-seq data. We identified cell-specific
isoform switching events and predicted the functional outcome of the identified switches. Our data
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indicates a distinct and unique pattern of switching behaviour in the investigated cell lines, which
could possibly correlate with their specific tumour stage. Comparing the two HL cell lines in our
study, we identified a higher number of STPs (three) available in the higher stage cancer cell line
(L-1236, stage IV) than the lower stage cell line (HD-MY-Z, stage IIIb) with only one STP (Figure 1B).
Moreover, while changes in the potential consequences (such as ORF length and domains present)
in the STP of LCL-HO are present, these are not statistically significant. In contrast, in HD-MY-Z,
which displays one STP, the changes in the potential functional consequences of pairwise expression
switching are significant. Also, for L-1236, the STPs have significant changes and even opposing
changes in the potential consequences of the pairwise expression switching of isoforms. Through
enrichment analysis for the genes that undergo temporal changes in isoform expression in each cell
line, we identified several pathways, which are related to cancer (SLIT/ROBO and FGFR2 signalling
pathway). Previous studies indicate that the SLIT/ROBO pathway acts as master regulator for multiple
oncogenic signalling pathways including the CD20, mTOR, VEGF and EGFR pathways in several
cancer types including lung cancer, colon cancer and lymphoma [33]. Similar to the SLIT/ROBO
pathway, the FGFR2 signalling pathway plays a role in cancer progression as well. Since FGFR2
pathway interacts with major signalling pathways, including BMP, WNT, Notch and Hedgehog, its
aberrant activity is associated with developmental defects resulting in metabolic disorders, and cancer
including lymphoma (reviewed in [34]).
We further analysed a reduced set of genes that present splicing switches in a time-dependent
manner. In particular, out of the top 20 genes with largest expression difference between the isoforms
we identified the JCHAIN, NME2 and HNRNPH1 genes (for the LCL-HO cell line), CD44, TNFRSF12A
and HNRNPA1 (for the HD-MY-Z cell line) and NFKB2, PPP4C and HSPD1 (for the L-1236 cell
line), which have an impact in tumorigenesis. Transcript variants of HNRNPH1 were shown to be
differentially involved in tumorigenesis. Overall, positive expression of HNRNPH1 is associated
with poor tumour differentiation degree [35,36]. The NME2 gene can act as a metastasis suppressor
by altering telomere function and telomere length in lung cancer and fibroblasts [39,43]. CD44 is
epigenetically regulated in Hodgkin and non-Hodgkin lymphomas and is reported to be unmethylated
in the L-1236 cell line [44]. Several studies have identified various isoforms of the CD44 gene [45].
Particularly, the CD44v isoforms are involved in specific signalling pathways. While the CD44v3
isoform bind several heparan sulfate-binding growth factors such as fibroblast growth factors (FGFs)
and heparin-binding epidermal growth factor (EGF), the CD44v6 isoform contains a binding site for
hepatocyte growth factor (HGF) and VEGF inducing CD44v6/HGF/cMet complex formation, leading
to c-Met or HGF-induced Ras signalling activation [45]. Cancer cells often express a variety of CD44
isoforms, which enables the regulation of multiple oncogenic pathways required for cancer progression
and tumour development [40,46,47]. The PPP4C gene is required for the correct DNA damage repair
functioning upon a double strand break. Moreover, it was shown to be involved in the TNF and
NF-kB pathways. It acts as a signalling component connecting the TNF signal to the JNK pathway [48].
HSPD1 encodes a heat-shock family protein chaperone that exhibits elevated expression in Hodgkin’s
and large cell lymphoma and is involved in the B and T cell immune response [49].
Altogether, these genes encode for functionally different isoforms involved in vital cellular and
tumorigenic processes and hence, the temporal change in their isoform balance could imply subsequent
changes in tumour progression.
3.2. Putative Impact of Splicing Switches in the Fine-Tuning of the TNF Pathway: Survival vs. Apoptosis
It was recently reported, that splicing isoforms of the main elements within the TNF pathway can
have an impact on both inflammation and cancer and, hence, affect the outcome of the pathway [21].
Among the genes identified by our bioinformatics approach, are several members of the TNF and
TNF-related signalling pathway that show a rhythmic pattern of isoform expression: TNFRSF12A and
SHARPIN in the HD-MY-Z cell line, NFKB2 in the L-1236 cell line and TRAF1 in the LCL-HO cell line.
The TNF receptor superfamily 12A gene (TNFRSF12A) displays a time-dependent isoform generation in
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the HD-MY-Z cell line. Surprisingly, one of the transcripts for which a temporal isoform generation was
detected undergoes NMD, which may influence its functional outcome in time. In cancer, TNFRSF12A
can promote angiogenesis and endothelial cell proliferation. It was reported that TNFRSF12A knockout
inhibits hepatocellular carcinoma cell proliferation and migration in vitro [50,51]. TRAF1 belongs to
the TNF receptor-associated factors that regulates the activation of NF-kB and JNK pathways and
is involved in both cell survival and apoptosis [52,53]. Another important component of the TNF
signalling pathway is SHARPIN, which belongs to the LUBAC protein complex involved in the NF-kB
and apoptotic signalling pathways. It was shown that SHARPIN deficiency leads to rapid cell death
upon TNF stimulation via FADD- and Caspase-8-dependent pathways [54]. Another example of a
TNF-related component found in our analysis is the nuclear factor kappa B subunit 2 (NFKB2) for
which we identified splicing switches in the L-1236 cell line. Studies have indicated that NFKB2 may
be involved in HL development (in L-1236) and the NF-κB-mediated transcriptional repression of
the clock feedback limb could cause circadian disruption in response to inflammation in mice [55,56].
In the LCL-HO cell line, TNF receptor associated factor 1 (TRAF1) showed a temporal pattern of
isoform expression. Interestingly, yeast two-hybrid interaction assays revealed that TNFRSF12A
binds to members of the TRAF family including TRAF1 and thereby activates the NF-κB signalling
pathway [35]. Components of the NF-κB signalling pathway are affected by AS events, which could
either inhibit or enhance the outcome response [57].
Taken together, the results of our study further reinforce the hypothesis, that AS could potentially
fine-tune the outcome of the TNF signalling pathway in a time-dependent manner. This adds a hidden
layer of temporal regulation in the TNF pathway that will require further experimental studies to fully
validate and further evaluate the impact of our findings in tumorigenesis.
4. Materials and Methods
4.1. Cell Culture
The Hodgkin lymphoma cell lines, HD-MY-Z (DSMZ—#ACC 346) and L-1236 (DSMZ—#ACC
530), and the B lymphoblastoid cell line, LCL-HO (DSMZ—#ACC 185) were maintained in RPMI 1640
(Gibco) supplemented with 1% penicillin-streptomycin (Gibco) and 10% foetal bovine serum (Gibco)
and incubated at 37 ◦C with 5% CO2 atmosphere.
4.2. Sampling and RNA Extraction
Cells were seeded in 35 mm dishes with a density of 5 × 105 cells/dish and synchronized by
fresh medium addition. Cells were collected every three hours, in triplicates and the pellets were
stored at −80 ◦C. Total RNA was isolated using the RNeasy extraction kit (Qiagen), including DNase
digestion, according to manufacturer’s instructions. Cells were lysed with 350 µL RLT buffer and
the lysate was homogenized. Total RNA concentration was determined using NanoDrop® ND-1000
ultraviolet–visible (UV–Vis) spectrophotometer and stored at −80 ◦C. A total of 33 time-course data
sets (sampling every three hours between ZT12h and ZT42h) was produced for subsequent sequencing.
4.3. RNA-Sequencing
For RNA-sequencing the total RNA was processed by Illumina standard protocols to prepare
the mRNA-Seq library, followed by deep sequencing in a bi-directional, 75-base mode on an Illumina
NextSeq sequencer. The RNA-sequencing was performed in Genomics Core Facility at the European
Molecular Biology Laboratory (EMBL) in Heidelberg.
4.4. Enrichment Analysis
Enrichment analysis was performed with the DOSE [58] (ver. 3.8.2) for Disease Ontology and
ReactomePA (ver. 1.26.0) R packages using Reactome Pathways. All reactome pathway enrichment
was performed with a p-value cut-off of 0.05 and Bonferroni Hochberg correction for multiple testing
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against default “universe” background set of genes with a q-value cut-off of 0.2. Disease ontology
enrichment was performed with the disease ontology as ontology of choice and p-value cut-off of 0.05
as well as q-value cut-off of 0.5. In all cases, the top 10 enriched terms (if present) were plotted.
4.5. RNA-Seq Data Processing
The time course paired-end RNA-seq samples were quantified with the Salmon software package
against the reference transcriptome provided by the EMBL. The transcriptome version used was
Homo_sapiens.GRCh38.cdna.A single sample represents each time point, no replicates were used.
Noise was added to the data to simulate potential biological variation with the R function jitter and
“factor” parameter set to 10 as well as amount parameter set to 2.
4.6. Detection and Visualization of Splicing Switches
For the detection of splicing switches over time the TSIS R package (ver. 0.2.0) was used
with “mean” as the detection method and a spline degree of 4 to focus on isoforms with a period
close to 24 h. Isoform switches were visualized with the TSIS [30] package and in detail with the
IsoformSwitchAnalyzeR R package. For the TSIS package, the MEAN scoring method was used.
Filtering of the results was done with TSIS with a probability cut-off of 0.5, difference cut-off of 1,
p-value cut-off of 0.001, a minimal time in interval of 2, correlation cut-off of 0, lower time of 0 h and
upper time of 30 h (experimental time) without a reduction to the most abundant isoforms. For the
analysis of coding functionality, we used a coding potential cut-off of 0.725. For the visualization of
pairwise comparisons between the STPs we used a difference cut-off of 0.1. Genes with single isoform
are removed from the pairwise STP analysis.
Computation of abundance differences (from Guo et al. [30]): Metric 2 indicates the magnitude of
the switch. Higher values mean larger changes in abundances before and after the switch. S2 is the
sum of average abundance differences of the two isoforms in both intervals:
S2(isoi, isoj|I1, I2) = d(isoi, isoj|I1) + d(isoi, isoj|I2) (1)
where d(isoi, isoj|Ik) is the average difference of abundances between isoi and isoj in the interval Ik, k =
1,2 is defined as:
d(isoi, isoj|Ik) = (1/|Ik|)∑mIk|exp(isoi|smIk , Ik) − exp (isoj|smIk, Ik)| (2)
|Ik| is the number of samples in interval Ik and exp(isoi|smIk, Ik) is the expression of isoi of sample smIk
in interval Ik.
4.7. Data Access
The RNA-sequencing data was submitted to the GEO repository and will be released upon
publication of the manuscript.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/
5/1182/s1. Sup. Figure S1: Statistical significance testing of the functional events for the LCL-HO, HD-MY-Z
and L-1236 cell lines shows multiple cases of important domain loss or gain enrichment. The events detected in
HD-MY-Z STP1 and L 1236 STP1 and STP2 contain changes with potential consequence such as domain gain/loss
with a 95% confidence interval. Interestingly, L-1236 STP1 and STP2 show opposed changes. Sup. Figure S2:
Switches between isoform expression in the LCL-HO and HD-MY-Z cell lines reveal alternative splicing start
and termination sites as the main event present in the switches. Testing for alternative splicing mechanisms
such as Exon Skipping (ES), Multiple Exon Skipping (MES), Multiple Exclusive Exons (MEE), Intron Retention
(IR), Alternative 5′ Splice Site (A5), Alternative 3′ Splice Site (A3), Alternative Transcription Start Site (ATSS)
and Alternative Transcription Termination Site (ATTS) for the LCL-HO and HD-MY-Z cell lines. Sup. Figure S3:
Switches between isoform expression in the L-1236 cell line reveal alternative splicing start and termination sites
as the event present in the switches for all STPs. Testing for alternative splicing mechanisms such as Exon Skipping
(ES), Multiple Exon Skipping (MES), Multiple Exclusive Exons (MEE), Intron Retention (IR), Alternative 5′ Splice
Site(A5), Alternative 3′ Splice Site (A3), Alternative Transcription Start Site (ATSS) and Alternative Transcription
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Termination Site (ATTS) for the L-1236 cell line. Sup. Figure 4: Enrichment of Reactome pathway and disease
ontology terms points at the increasing specificity of the genes switching over time in a cell line specific manner.
(A) We performed Reactome pathway enrichment for the genes displaying switching between isoform expression
in time in the LCL-HO cell line only. The ROBO pathway as well as DNA repair are enriched. Disease ontology
terms related show relation to cancer. (B) We performed Reactome pathway enrichment for the genes displaying
switching between isoform expression in time in the HD-MY-Z cell line. The ROBO pathway enrichment present
in the LCL-HO cell line (Figure 4) is also present in the HD-MY-Z cell line. (C) Reactome pathway enrichment
for the genes displaying switching between isoform expression in time in the L-1236 cell line only. A disease
ontology enrichment analysis yielded no results due to the low number of genes. Sup. Figure 5: The development
of the expression of the isoforms ENST00000442819.6 and ENST00000523449.5 of the HNRNPH1 gene over time
shows marked differences between the three cell lines (A,B,C) While switching is present in LCL-H0, in HD-MY-Z
the ENST00000442819.6 isoform dominates while in L-1236 the two isoforms switch. The expression of the two
isoforms is strong in all three cell lines. Sup. Figure 6: Decrease in overall gene expression for the NME2 and
JCHAIN isoforms of the LCL-HO cell lines coexists with the increase of expression of individual isoforms (A)
Pairwise comparison between the time points 24 h and 33 h (STP) of the LCL-HO cell line for the NME2 gene.
While the overall gene expression over time decreases, the expression of the ENST00000512737.5 isoform increases.
(B) The decrease of expression of the ENST00000543780.5 isoform of JCHAIN over time (STP) leads to an increase
in the expression of the ENST00000510437.5 isoform. Sup Table S1: Pairwise switching transcripts (isoforms)
after filtering and corresponding genes for the LCL-HO cell line. Sup. Table S2: Pairwise switching transcripts
(isoforms) after filtering and corresponding genes for the HD-MY-Z cell line. Sup. Table S3: Pairwise switching
transcripts (isoforms) after filtering and corresponding genes for the L-1236 cell line. Sup. Table S4: List of genes
for which pairwise isoform expression switching over time was detected for the LCL-HO cell line. Sup. Table
S5: List of genes for which pairwise isoform expression switching over time was detected for the HD-MY-Z cell
line. Sup. Table S6: List of genes for which pairwise isoform expression switching over time was detected for the
L-1236 cell line. Sup. Table S7: List of the 89 intersecting genes for which pairwise switching in isoform expression
was detected for all three cell lines. Sup. Table S8: Top 10 enriched Reactome pathways for the 89 intersecting
genes (Figure 3). Sup. Table S9: Top 10 enriched DO terms for the 89 intersecting genes (Figure 3). Sup. Table
S10: Top 10 enriched Reactome pathways for all genes with switches for the LCL-HO cell line (Figure 3). Sup.
Table S11: Top 10 enriched Reactome pathways for all genes with switches for the HD-MY-Z cell line (Figure 3).
Sup. Table S12: Top 10 enriched Reactome pathways for all genes with switches for the L-1236 cell line (Figure 3).
Sup. Table S13: Top 10 enriched Reactome pathways for the unique genes with switches for the LCL-HO cell line
(Figure S4). Sup. Table S14: Top 10 enriched Reactome pathways for unique genes with switches for the HD-MY-Z
cell line (Figure S4). Sup. Table S15: Top 10 enriched Reactome pathways for unique genes with switches for the
L-1236 cell line (Figure S4). Sup. Table S16: Top 10 enriched DO terms for unique genes with switches for the
LCL-HO cell line (Figure S4). Sup. Table S17: Top 10 enriched DO terms for unique genes with switches for the
HD-MY-Z cell line (Figure S4).
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